Guidelines stress the importance of the simultaneous management of multiple
cardiovascular risk factors. This can in part be achieved by coadministration of lipid …

The AVALON study was a randomized, multicenter trial to assess the efficacy and safety of
coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia …

Amlodipine/atorvastatin (Caduet®) is a once-daily fixed-dose combination of the
dihydropyridine calcium channel antagonist amlodipine and the HMG-CoA reductase …

Amlodipine/atorvastatin (Caduet®) is a single-tablet, fixed-dose combination of the
dihydropyridine calcium channel antagonist amlodipine and the HMG-CoA reductase …

The Gemini Study was a 14‐week, open‐label, noncomparative, office‐based, multicenter
trial to evaluate single‐pill therapy in the treatment of concomitant hypertension and …

The effects of combined atorvastatin and amlodipine on blood pressure (BP) and low-
density lipoprotein (LDL) cholesterol levels were investigated in 134 patients with …

This multicenter, randomized, double‐blind, parallel‐group phase III clinical trial aimed to
investigate the efficacy and safety of a rosuvastatin+ amlodipine combination compared with …

Single‐pill amlodipine besylate/atorvastatin calcium (Caduet®, Pfizer Inc, NY, USA) is the
first therapy aimed at the simultaneous treatment of hypertension (HTN) and dyslipidaemia …

Amlodipine/atorvastatin combination therapy has been demonstrated to be an effective
approach for the management of concomitant hypertension (HTN) and dyslipidemia (DYS) …

BACKGROUND: We hypothesized that atorvastatin combined with amlodipine has additive
beneficial vascular and metabolic effects that are superior to monotherapy in patients with …